1 January–31 December
|
kEUR |
2025 |
2024 |
|
|
|
|
|
|
|
Revenue |
389,327 |
336,792 |
|
|
Other operating income |
2,622 |
1,978 |
|
|
Total income |
|
391,949 |
338,770 |
|
|
|
|
|
|
Cost of sales |
|
-325,336 |
-299,422 |
|
Gross profit / (loss) |
|
66,613 |
39,348 |
|
|
|
|
|
|
Marketing and sales expenses |
-4,473 |
-3,866 |
|
|
Research expenses |
-2,282 |
-1,095 |
|
|
General and administrative expenses |
-51,169 |
-41,751 |
|
|
Total operating expenses |
|
-57,924 |
-46,712 |
|
|
|
|
|
|
Operating result (EBIT) |
|
8,689 |
-7,364 |
|
|
|
|
|
|
Financial income |
1,843 |
6,802 |
|
|
Financial expenses |
-30,589 |
-17,583 |
|
|
Total financial result |
|
-28,746 |
-10,781 |
|
|
|
|
|
|
Result before income taxes |
|
-20,057 |
-18,145 |
|
|
|
|
|
|
Income tax |
-1,112 |
-1,419 |
|
|
Result for the year |
|
-21,169 |
-19,564 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
-21,169 |
-19,564 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
-0.64 |
-0.59 |
|
|
Earnings per share in EUR, diluted |
-0.64 |
-0.59 |